Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation

Bente Arboe, Maja Halgren Olsen, Anne Katrine Duun-Henriksen, Jette Sønderskov Gørløv, Kristina Fruerlund Nielsen, Rasmus Heje Thomsen, Charlotte Madsen, Søren Ramme Nielsen, Susanne Oksbjerg Dalton, Peter de Nully Brown

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox's proportional hazards model. Median overall survival was 6.8 years, median progression-free survival was 2.6 years, and treatment-related mortality at Day 100 was 6%. Factors associated with a significant adverse impact on survival were age, primary refractory disease, prolonged hospitalization during salvage treatment, and performance status >0 prior to conditioning therapy. Reconsideration of ASCT for those patients may be required in order to select the right patients for this toxic procedure.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Vol/bind59
Udgave nummer5
Sider (fra-til)1153-1162
ISSN1042-8194
DOI
StatusUdgivet - 4. maj 2018

Fingeraftryk

Lymphoma, Large B-Cell, Diffuse
Age Factors
Lymphoma
Registries
Salvage Therapy
Poisons
Patient Rights
Proportional Hazards Models
Disease-Free Survival
Medical Records

Citer dette

Arboe, Bente ; Halgren Olsen, Maja ; Duun-Henriksen, Anne Katrine ; Gørløv, Jette Sønderskov ; Nielsen, Kristina Fruerlund ; Thomsen, Rasmus Heje ; Madsen, Charlotte ; Ramme Nielsen, Søren ; Dalton, Susanne Oksbjerg ; Brown, Peter de Nully. / Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. I: Leukemia and Lymphoma. 2018 ; Bind 59, Nr. 5. s. 1153-1162.
@article{1af97bf75eb64557a706f2b00777ae55,
title = "Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation",
abstract = "In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox's proportional hazards model. Median overall survival was 6.8 years, median progression-free survival was 2.6 years, and treatment-related mortality at Day 100 was 6{\%}. Factors associated with a significant adverse impact on survival were age, primary refractory disease, prolonged hospitalization during salvage treatment, and performance status >0 prior to conditioning therapy. Reconsideration of ASCT for those patients may be required in order to select the right patients for this toxic procedure.",
keywords = "Journal Article, prognostication, lymphoma and Hodgkin disease, Transplant toxicity, Severity of Illness Index, Prognosis, Follow-Up Studies, Humans, Middle Aged, Drug Resistance, Neoplasm, Male, Survival Rate, Transplantation, Autologous, Combined Modality Therapy, Lymphoma, Non-Hodgkin/mortality, Lymphoma, Large B-Cell, Diffuse/mortality, Female, Hospitalization/statistics & numerical data, Aged, Hematopoietic Stem Cell Transplantation/mortality, Cohort Studies",
author = "Bente Arboe and {Halgren Olsen}, Maja and Duun-Henriksen, {Anne Katrine} and G{\o}rl{\o}v, {Jette S{\o}nderskov} and Nielsen, {Kristina Fruerlund} and Thomsen, {Rasmus Heje} and Charlotte Madsen and {Ramme Nielsen}, S{\o}ren and Dalton, {Susanne Oksbjerg} and Brown, {Peter de Nully}",
year = "2018",
month = "5",
day = "4",
doi = "10.1080/10428194.2017.1369061",
language = "English",
volume = "59",
pages = "1153--1162",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor & Francis",
number = "5",

}

Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation. / Arboe, Bente; Halgren Olsen, Maja; Duun-Henriksen, Anne Katrine; Gørløv, Jette Sønderskov; Nielsen, Kristina Fruerlund; Thomsen, Rasmus Heje; Madsen, Charlotte; Ramme Nielsen, Søren; Dalton, Susanne Oksbjerg; Brown, Peter de Nully.

I: Leukemia and Lymphoma, Bind 59, Nr. 5, 04.05.2018, s. 1153-1162.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation

AU - Arboe, Bente

AU - Halgren Olsen, Maja

AU - Duun-Henriksen, Anne Katrine

AU - Gørløv, Jette Sønderskov

AU - Nielsen, Kristina Fruerlund

AU - Thomsen, Rasmus Heje

AU - Madsen, Charlotte

AU - Ramme Nielsen, Søren

AU - Dalton, Susanne Oksbjerg

AU - Brown, Peter de Nully

PY - 2018/5/4

Y1 - 2018/5/4

N2 - In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox's proportional hazards model. Median overall survival was 6.8 years, median progression-free survival was 2.6 years, and treatment-related mortality at Day 100 was 6%. Factors associated with a significant adverse impact on survival were age, primary refractory disease, prolonged hospitalization during salvage treatment, and performance status >0 prior to conditioning therapy. Reconsideration of ASCT for those patients may be required in order to select the right patients for this toxic procedure.

AB - In patients with relapsed diffuse large B-cell lymphoma (DLBCL), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is standard treatment. Here, we aim to identify factors associated with survival in patients undergoing ASCT. A total of 369 patients with relapsed DLBCL undergoing ASCT from 2000 to 2012 were identified in the Danish National Lymphoma Registry. Information on clinical and socioeconomic factors was obtained from medical records and national registries. Factors associated with survival were assessed using a Cox's proportional hazards model. Median overall survival was 6.8 years, median progression-free survival was 2.6 years, and treatment-related mortality at Day 100 was 6%. Factors associated with a significant adverse impact on survival were age, primary refractory disease, prolonged hospitalization during salvage treatment, and performance status >0 prior to conditioning therapy. Reconsideration of ASCT for those patients may be required in order to select the right patients for this toxic procedure.

KW - Journal Article

KW - prognostication

KW - lymphoma and Hodgkin disease

KW - Transplant toxicity

KW - Severity of Illness Index

KW - Prognosis

KW - Follow-Up Studies

KW - Humans

KW - Middle Aged

KW - Drug Resistance, Neoplasm

KW - Male

KW - Survival Rate

KW - Transplantation, Autologous

KW - Combined Modality Therapy

KW - Lymphoma, Non-Hodgkin/mortality

KW - Lymphoma, Large B-Cell, Diffuse/mortality

KW - Female

KW - Hospitalization/statistics & numerical data

KW - Aged

KW - Hematopoietic Stem Cell Transplantation/mortality

KW - Cohort Studies

U2 - 10.1080/10428194.2017.1369061

DO - 10.1080/10428194.2017.1369061

M3 - Journal article

C2 - 28868963

VL - 59

SP - 1153

EP - 1162

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -